DMA Diamedica Therapeutics

DiaMedica (TSX VENTURE:DMA) today announces that it has been selected to present
a Late Breaking Science Poster featuring pre-clinical cardiovascular data on
DM-204 at the 2012 American Heart Association's Scientific Sessions being held
in Los Angeles, CA, November 3-7, 2012. 


Mark Williams, PhD., Vice President of Research at DiaMedica will present the
poster presentation titled, "A Novel Bradykinin-2 Receptor Agonist Antibody that
Improves Diabetic and Cardiovascular Endpoints." DiaMedica is developing DM-204
for the treatment of diabetes and cardiovascular disease.


"We are delighted to have the opportunity to share the results and mechanism of
our G-protein coupled receptor agonist antibody," commented Rick Pauls, Chairman
and CEO of DiaMedica. "Cardiovascular disease is a major complication of
diabetes and the leading cause of early death among people with diabetes. DM-204
could be a promising treatment for diabetes and cardiovascular disease if it
shows the benefit in future human trials."


About DiaMedica

DiaMedica is a biopharmaceutical company focused on discovery and development of
novel therapeutic compounds for diabetes and other major, medically-unmet
diseases. DiaMedica's lead compound, DM-199, is a recombinant human protein that
represents a novel approach to treating Type 1 and Type 2 diabetes. DiaMedica is
also developing a novel monoclonal antibody, DM-204 as a treatment for Type 2
diabetes. Chronic treatment with DM-204 in a Type 2 diabetes model resulted in
significant improvement in blood glucose control and HbA1c levels and also
significant decreases in blood pressure and serum cholesterol.


DiaMedica's DM-199 and DM-204 were both named Windhover's "2011 Top 10
Cardiovascular/Metabolic Projects to Watch". The Company is listed on the TSX
Venture Exchange under the trading symbol 'DMA'.


Caution Regarding Forward-Looking Information

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Company's filings with Canadian securities regulatory authorities. Should one or
more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Company undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024